WEBINAR SERIES: Modern medicines series SGLT2 Inhibitors: What we need to know

About the series

Over 3 programmes, Professor Cliff Bailey and colleagues will be providing concise evidence-based guidance to contemporary medications and their application in daily care.

The aim: To assess the clinical evidence and opportunities offered by sodium-glucose co-transporter-2 (SGLT2) inhibitors in the management of type 2 diabetes and its cardio-renal complications.

Objectives:

• Understand the mode of action of SGLT2 inhibitors to inhibit the reabsorption of filtered glucose by the kidney
• Appreciate the metabolic effects of SGLT2 inhibitors on glycaemic control and body weight control in the management of type 2 diabetes
• Assess the effects of SGLT2 inhibitors on cardiac and vascular function
• Evaluate the role of SGLT2 inhibitors in the management of blood pressure, heart failure and atherosclerotic disease with and without type 2 diabetes
• Examine the emerging evidence for reno-protective effects of SGLT2 inhibitors
• Consider the potential opportunities for SGLT2 inhibitors in the management of diabetic kidney disease

Included in each programme:

• A one hour webinar including a live Q&A discussion
• Downloadable slides to print off and keep
• A downloadable factsheet summarising the guidance
• A case study based CPD learning module with certificate upon completion

The series will complete with 2 further update webinars later in the year, dates and times tbc.

Programme 1 – Understanding SGLT2 inhibition Tuesday 9th February, 19.00 Speaker: Professor Cliff Bailey Type 2 diabetes and SGLT2 inhibitors in context Type 2 diabetes as a metabolic and cardio-renal disease Different glucose-lowering therapies The SGLT2 inhibitor class Mechanism of SGLT2 inhibition Speaker: Professor Vinod Patel Managing glycaemic control and body weight Glucose control and weight control in RCTs Real world evidence of efficacy  Tolerability and safety profiles Positioning in treatment algorithms for type 2 diabetes

Programme 2 – SGLT2 inhibitors and the heart Tuesday 23rd February, 19.00 Speaker: Professor Cliff Bailey Effects of SGLT2 inhibitors on cardiovascular function Cardiovascular disease in type 2 diabetes SGLT2 inhibitors lower blood pressure SGLT2 inhibitors reduced heart failure risk Mechanisms of SGLT2 inhibitors on heart and circulation Speaker: Dr Martin Hadley-Brown Role of SGLT2 inhibitors in the management of CV disease Improve BP control independently of other antihypertensives Reduce risk of new onset or worsening heart failure  May benefit atherosclerotic cardiovascular disease Positioned in algorithms for type 2 diabetes by CV effects

Programme 3 – SGLT2 inhibitors and the kidney Tuesday 9th March, 19.00 Speaker: Professor Cliff Bailey Reno-protective effects of SGLT2 inhibitors Kidney disease in type 2 diabetes SGLT2 inhibitors and glomerular filtration rate SGLT2 inhibitors reduced albuminuria Reno-protective mechanisms of SGLT2 inhibitors Speaker: Dr Pam Brown SGLT2 inhibitors in the management diabetic kidney disease Slow decline in glomerular filtration rate Reduce albuminuria  Delay progression of CKD without diabetes Value in prevention and treatment of diabetic kidney disease

The series will complete with 2 further update webinars later in the year, dates and times tbc.

Your programme presenters

	Professor Cliff Bailey Emeritus Professor of Clinical Science, Aston University, Birmingham		Professor Vinod Patel Professor, Diabetes and Clinical Skills, Warwick Medical School. Honorary Consultant in Endocrinology and Diabetes, George Eliot Hospital, Nuneaton
	Dr Martin Hadley-Brown FRCGP, Hughes Hall, University of Cambridge		Dr Pam Brown GP, SA1 Medical Practice, Swansea

Plus each programme has

• downloadable slides to print off and keep
• a downloadable factsheet of practical guidance
• an interactive CPD learning module with certificate upon completion

If you cannot attend the broadcast, the webinar will be available on-demand 24 hours after the live event.